Show simple item record

dc.contributor.authorTurnbull, C
dc.contributor.authorLoveday, C
dc.contributor.authorIzatt, L
dc.contributor.authorEllard, S
dc.date.accessioned2020-09-30T13:36:29Z
dc.date.issued2018-09
dc.identifier.citationThe Journal of clinical endocrinology and metabolism, 2018, 103 (9), pp. 3518 - 3519
dc.identifier.issn0021-972X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4102
dc.identifier.eissn1945-7197
dc.identifier.doi10.1210/jc.2018-01094
dc.formatPrint
dc.format.extent3518 - 3519
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectThyroid Neoplasms
dc.subjectMutation
dc.subjectProto-Oncogene Proteins c-ret
dc.titleResponse to Letter to the Editor: "p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer".
dc.typeJournal Article
dcterms.dateAccepted2018-07-12
rioxxterms.versionofrecord10.1210/jc.2018-01094
rioxxterms.licenseref.startdate2018-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfThe Journal of clinical endocrinology and metabolism
pubs.issue9
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.publication-statusPublished
pubs.volume103
pubs.embargo.termsNot known
dc.contributor.icrauthorTurnbull, Clareen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record